FluShield Manufacturer to Send Letter on Price, Allocation
November , 2000
I would like to take this opportunity to provide you with an update concerning the delivery and production of Wyeth Lederle Vaccines' influenza vaccine, FluShield. As you are aware, the production and distribution of Flu vaccine continues to be delayed for all manufacturers. The A/Panama (H3N2) strain of the vaccine has been a particularly difficult strain to produce and has resulted in lower than normal yields. Additionally, we continue to address issues that challenge our production efforts this year at our Marietta facility, where FluShield is manufactured. We began distributing this year's vaccine during the week of October 16th.
The CDC issued its Adjunct Influenza Vaccine Use Recommendations for the 2000-2001 Influenza Season in the July 14th issue of MMWR (Morbidity and Mortality Weekly Report). In support of the public health priorities set forth in the CDC guidelines (summary attached hereto) we shipped our first available doses to all nursing home accounts identified in our customer database. With respect to all remaining FluShield doses, we are implementing a fair and equitable allocation by week to all customers who have ordered vaccine from us. We anticipate that we will have shipped 54% of all orders by the end of November and the balance of available doses by the end of December.
As of February 15, 2000 we had established our selling price for FluShield and this price has not changed. We are aware of instances where others are offering FluShield at prices significantly above our selling price. Wyeth has not increased, or otherwise sold any FluShield at prices above those established in February. Further, we have no control over such prices and do not receive any revenue beyond our original selling price.
We support the CDC's guidelines that distribution should go first to those in greatest need. As we cannot determine the level of risk of the patients within your care, we strongly urge that the CDC guidelines to prioritize patients for this vaccine be followed. We have also requested that wholesalers and Distributors distribute FluShield in support of these guidelines.
We want to assure you that we are making every effort to provide you and the public with FluShield as quickly and responsibly as possible. We sincerely apologize for any inconvenience this may cause you and appreciate your patience in this matter.
Adjunct Influenza Vaccine Use Recommendations for the 2000-2001 Influenza Season